The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

The pathogenesis, predictors, and prevention of bone complications in patients with castration-resistant metastatic prostate cancer

Authors:

Alekseev B.Ia., Niushko K.M., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(4): 81‑85

Read: 3456 times

Download PDF (RU)
Contact the author
Table of contents

THE PATHOGENESIS, PREDICTORS, AND PREVENTION OF BONE COMPLICATIONS IN PATIENTS WITH CASTRATION-RESISTANT METASTATIC PROSTATE CANCER
THE PATHOGENESIS, PREDICTORS, AND PREVENTION OF BONE COMPLICATIONS IN PATIENTS WITH CASTRATION-RESISTANT METASTATIC PROSTATE CANCER

To cite this article:

Alekseev BIa, Niushko KM, Kaprin AD. The pathogenesis, predictors, and prevention of bone complications in patients with castration-resistant metastatic prostate cancer. P.A. Herzen Journal of Oncology. 2013;2(4):81‑85. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of early predictors in diagnosis of stapler suture and anastomotic failure in bariatric patients. Piro­gov Russian Journal of Surgery. 2025;(3):76-86
Postoperative outcomes and role of adju­vant therapy in common bile duct cancer. Piro­gov Russian Journal of Surgery. 2025;(12):69-79
Abstract:

Castration-resistant metastatic prostate cancer (CRMPC) is a prognostically unfavorable disease, for which conventional hormonal methods are ineffective. Frequent metastatic involvement of bones is a cause of their complications, which substantially worsens quality of life and survival in patients. The paper gives the results of investigations to assess the cause and progression of bone metastases in patients with CRMPC, characterizes the main predictors of bone complications in this category of patients, and outlines methods for the prevention and therapy of these complications.

Keywords:

castration-resistant prostate cancer
bone complications
predictors
spinal cord compression
pathological fractures

Authors:

Alekseev B.Ia.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Niushko K.M.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Kaprin A.D.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Close metadata

References:

  1. Chissov V.I., Starinskii V.V., Petrova G.V., red. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2011 godu. M.; 2012.
  2. Ilic D., O'Connor D., Green S.T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007; 18 (3): 279-85.
  3. Bartsch G., Horninger W., Klocker H. et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001; 58 (3): 417-24.
  4. Andriole G.L., Crawford E.D., Grubb R.L. 3rd. et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 2009; 360 (13): 1310-9.
  5. Schröder F.H., Hugosson J., Roobol M.J. et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360 (13): 1320-8.
  6. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann. Intern. Med. 1993; 118: 804-18.
  7. Abrahamson Per-Anders. Revolutions in the management of hormone-refractory prostate cancer. Eur. Urol. 2003; Suppl. 2: 1-2.
  8. Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J. Clin. Oncol. 1999; 17: 2506-13.
  9. Berruti A., Tucci M., Mosca A. et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br. J. Cancer. 2005; 93 (6): 633-8.
  10. Harada M., Iida M., Yamaguchi M. et al. Analysis of bone metastasis of prostate adenocarcinoma in 137 autopsy cases. Adv. Exp. Med. Biol. 1992; 324: 173-82.
  11. Clarke N.W., McClure J., George N.J. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur. Urol. 1993; 24: 286-90.
  12. Clarke N.W., McClure J., George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 1991; 68: 74-80.
  13. Garnero P., Buchs N., Zekri J. et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer. 2000; 82: 858-64.
  14. Berruti A., Dogliotti L., Bitossi R. et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol .2000; 164: 1248-53.
  15. Kostenuik P.J., Singh G., Orr F.W. Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Cli. Exp. Metastasis. 1997; 15: 41-52.
  16. Rajan R., Vanderslice R., Kapur S. et al. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullar bone. Prostate. 1996; 28: 1-9.
  17. Boyle W.J., Simonet W.S., Lancey D.L. Osteoclast differentiation and activation. Nature. 2003; 423: 337-42.
  18. Holen I., Croucher P.I., Hamdy F.C. et al. Osteoprotegerin (OPG) is a survival factor for tumor prostate cancer cells. Cancer Res. 2002; 62: 1619-23.
  19. Wakchoure S., Swain T.M., Hentunen T.A. et al. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate. 2009; 69 (6): 652-61.
  20. Reddi A.H., Roodman D., Freeman C. et al. Mechanisms of tumor metastases to the bone: challenges and opportunities. J. Bone Miner. Res. 2003; 18: 190-4.
  21. Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A. et al. Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin. Oncol. 2003; 21: 1232-7.
  22. Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K. et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol. 2002; 20: 3972-82.
  23. Bayley A., Milosevic M., Blend R., Logue J., Gospodarowicz M., Boxen I. et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer. 2001; 92: 303-10.
  24. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. 2000; 163 (1): 181-6.
  25. Krupski T.L., Smith M.R., Chan Lee W., Pashos C.L., Brandman J., Wang Q. et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004; 101 (3): 541-9.
  26. Oefelein M.G., Ricchiuti V., Conrad W., Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 2002; 168 (3): 1005-7.
  27. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351 (15): 1502-12.
  28. George R., Jeba J., Ramkumar G., Chacko A.G., Leng M., Tharyan P. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst. Rev. 2008; (4):CD006716.
  29. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 2002; 94 (19): 1458-68.
  30. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L. et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann. Oncol. 2008; 19 (3): 420-32.
  31. Fizazi K., Garducci M., Smith M. et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011; 377 (9768): 813-22.
  32. Gregory C.W., He B., Johnson R.T. et al. A mechanism of androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001; 61: 4315-9.
  33. Sathiakumar N., Delzell E., Morrisey M.A. et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare benefi ciaries, 1999-2006. Prostate Cancer Prostat. Dis. 2011; 14: 177-83.
  34. Sartor A.O., Heinrich D., O'Sullivan J.M. et al. Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: interim results of a phase III trial (ALSYMPCA). Proc. Am. Soc. Clin. Oncol. 2012; 30 (Suppl.): abstr. 4551.
  35. Hussain M., Smith M.R., Sweeney C. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. Proc. Am. Soc. Clin. Oncol. 2011; 29 (Suppl.): abstr. 4516.
  36. Parker C., Nilsson S., Heinrich D. et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). Proc. Am. Soc. Clin. Oncol. 2012; 30 (Suppl.): abstr. LBA4512.
  37. Armstrong A.J., Garrett-Mayer E., de Wit R., Tannock I., Eisenberger M. Prediction of survival following fi rst-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin. Cancer Res. 2010; 16: 203-11.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.